Added to YB: 2026-06-10
Pitch date: 2026-04-12
CEVI.ST [bearish]
CellaVision AB (publ)
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally.
Market Cap
SEK 3.1B
Pitch Price
N/A
Price Target
N/A
Dividend
2.14%
EV/EBITDA
13.83
P/E
22.84
EV/Sales
3.91
Sector
Health Care Equipment and Supplies
Category
value
Show full summary:
CellaVision AB - $CEVI.ST
CEVI.ST (short): DCM leader losing share (80%→55-60% since 2021) to Mindray's MC-80 (60 slides/hr, $30k vs DI-60 $100k). ROIC fell 25%→13-14%. Reagents lack pricing power. Mgmt's 15% growth target unrealistic (~5% likely). At 3.6B SEK (~$388M), ~20x FCF too pricey; fair below $300M.
Read full article (10 min)